The Investor Relations website contains information about Ionis Pharmaceuticals, Inc.'s business for stockholders, potential investors, and financial analysts.
Search in Internal Sections Only. Search in External Sections Only. The Inline XBRL Viewer allows a user to quickly and easily review details of the tagged information in an Inline document by ...
"In the third quarter of 2025, we delivered strong revenue performance, highlighted by TRYNGOLZA’s nearly 70% increase over the prior quarter. As a result of this strength and our fourth quarter ...
CARLSBAD, Calif., July 20, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Novartis has completed patient enrollment of the pivotal Phase 3 Lp(a) HORIZON ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Nov. 8, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive results from the pivotal Phase 3 CORE and CORE2 studies of olezarsen in people ...
– Phase 3 enrollment completed in CORE, CORE2 and ESSENCE evaluating olezarsen for the treatment of severe hypertriglyceridemia, with results expected in 2H 2025 – Olezarsen is an investigational ...
“Today’s approval of ZANVASTRO begins a new chapter for people living with Alexander disease and their families, who have long faced this relentlessly progressive and often fatal disease with no ...
“The approval of TRYNGOLZA marks an historic advance for people who have long struggled to control their dangerously high triglycerides, providing the only approved therapy for sHTG to dramatically ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Dec. 2, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy ...
– Ulefnersen demonstrated a statistically significant improvement on the primary endpoint assessing functional impairment and survival in people living with FUS-ALS, supporting the potential to modify ...
CARLSBAD, Calif., Sept. 9, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the pricing of an underwritten public offering of 11,500,000 shares of its common stock. The ...
CARLSBAD, Calif.--(BUSINESS WIRE)--Sep. 22, 2025-- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced positive topline results from the pivotal study of zilganersen in children and adults ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results